Comparison · NCT00845026-838efbbb
LY2140023 vs Standard-of-Care (SOC): Number of Participants With Potentially Clinically Significant Changes in QT Intervals Electrocardiograms (ECGs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LY2140023 vs Standard-of-Care (SOC): Number of Participants With Potentially Clinically Significant Changes in QT Intervals Electrocardiograms (ECGs). Trial comparisons, record NCT00845026-838efbbb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00845026-838efbbb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0254 | 0.00868 | 0.0721 | wilson | |
| Risk in group 2 | 0.0315 | 0.0123 | 0.0782 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00607 | -0.0557 | 0.0444 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.807 | 0.185 | 3.53 | log | |
| Odds ratio, group 1 over group 2 | 0.802 | 0.176 | 3.66 | log | |
| Number needed to treat, for one fewer participant with the outcome on LY2140023 than on Standard-of-Care (SOC) | 165 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LY2140023 | 80 mg, oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg. | 3 | 118 | OG000 |
| Group 2 | Standard-of-Care (SOC) | aripiprazole: 10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).~olanzapine: 10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).~risperidone: 2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets). | 4 | 127 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Potentially Clinically Significant Changes in QT Intervals Electrocardiograms (ECGs)
- Description
A potentially clinically significant QT interval (high) is defined as a value meeting the criteria of (\> 450 millisecond \[ms\]) at anytime during the active treatment phase, provided it does not meet the criteria at baseline.~(analysis for Study Period III only)
- Time frame
- Baseline through 24 weeks
- Population
- All randomized participants with normal baseline measurement and at least one post-baseline measurement.
Source ClinicalTrials.gov
Trial
- Title
- A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
- NCT number
- NCT00845026
- Phases
- PHASE2
- Conditions
- Schizophrenia
- Interventions
- LY2140023, aripiprazole, olanzapine, risperidone
- Lead sponsor
- Denovo Biopharma LLC
- Results first posted
- 2022-09-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00845026?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00845026-838efbbb